S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
These are the Top 4 Stocks for Buybacks in 2024
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
Stock market today: Wall Street rises in premarket as bond markets stabilize and earnings roll in
Predicting a Bear Market: 7 Signs and Why it's Tough to Do
Abbott Laboratories Outlook is Healthy: Buy the Dip
Closing prices for crude oil, gold and other commodities
United Airlines Soars on Earnings Beat
CSX profit drops 10% despite railroad delivering 3% more freight in first quarter
These are the Top 4 Stocks for Buybacks in 2024

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Globus Medical, Inc. stock logo
GMED
Globus Medical
$51.18
-1.2%
$53.26
$43.38
$62.88
$7.01B1.08858,049 shs1.16 million shs
Haemonetics Co. stock logo
HAE
Haemonetics
$84.88
+0.8%
$78.72
$70.74
$95.26
$4.27B0.36382,792 shs359,409 shs
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$155.96
$155.74
$93.34
$156.22
$10.30B0.55656,912 shsN/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
$111.49
+1.5%
$111.81
$70.24
$140.23
$3.42B1.3446,982 shs260,450 shs
Nevro Corp. stock logo
NVRO
Nevro
$12.29
-3.2%
$14.63
$12.15
$39.67
$465.85M0.89365,406 shs289,158 shs
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Globus Medical, Inc. stock logo
GMED
Globus Medical
-1.18%-3.63%-0.91%-8.10%-11.38%
Haemonetics Co. stock logo
HAE
Haemonetics
+0.80%-1.50%+11.98%+1.65%-0.14%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.00%0.00%0.00%0.00%0.00%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
+1.49%-2.83%+8.99%+0.80%-15.47%
Nevro Corp. stock logo
NVRO
Nevro
-3.15%-7.59%-12.84%-32.25%-66.85%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Globus Medical, Inc. stock logo
GMED
Globus Medical
4.7413 of 5 stars
3.31.00.04.12.74.23.1
Haemonetics Co. stock logo
HAE
Haemonetics
3.9676 of 5 stars
2.34.00.04.32.31.71.9
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
2.273 of 5 stars
0.00.01.73.81.11.72.5
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.5845 of 5 stars
2.51.00.00.02.40.80.6
Nevro Corp. stock logo
NVRO
Nevro
1.745 of 5 stars
4.01.00.00.01.51.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Globus Medical, Inc. stock logo
GMED
Globus Medical
2.67
Moderate Buy$66.3329.61% Upside
Haemonetics Co. stock logo
HAE
Haemonetics
2.50
Moderate Buy$104.6723.31% Upside
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
N/AN/AN/AN/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
3.00
Buy$135.1121.19% Upside
Nevro Corp. stock logo
NVRO
Nevro
2.00
Hold$21.2372.75% Upside

Current Analyst Ratings

Latest HRC, GMED, NVRO, IRTC, and HAE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Nevro Corp. stock logo
NVRO
Nevro
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00
4/12/2024
Haemonetics Co. stock logo
HAE
Haemonetics
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$105.00
4/11/2024
Nevro Corp. stock logo
NVRO
Nevro
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$20.00 ➝ $16.00
4/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.00
4/3/2024
Nevro Corp. stock logo
NVRO
Nevro
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00
3/18/2024
Globus Medical, Inc. stock logo
GMED
Globus Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$60.00
2/23/2024
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$142.00 ➝ $133.00
2/23/2024
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$121.00 ➝ $133.00
2/23/2024
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$136.00 ➝ $137.00
2/22/2024
Nevro Corp. stock logo
NVRO
Nevro
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$23.00 ➝ $19.00
2/22/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $17.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Globus Medical, Inc. stock logo
GMED
Globus Medical
$1.02B6.79$3.56 per share14.36$29.32 per share1.75
Haemonetics Co. stock logo
HAE
Haemonetics
$1.17B3.69$5.02 per share16.92$16.22 per share5.23
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$3.02B3.41$9.29 per share16.79$28.56 per share5.46
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
$492.68M7.04N/AN/A$6.85 per share16.28
Nevro Corp. stock logo
NVRO
Nevro
$425.17M1.06N/AN/A$8.10 per share1.52

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Globus Medical, Inc. stock logo
GMED
Globus Medical
$122.87M$1.1743.7415.601.527.83%8.82%7.20%5/7/2024 (Confirmed)
Haemonetics Co. stock logo
HAE
Haemonetics
$115.40M$2.4634.5020.111.999.97%22.37%9.71%5/9/2024 (Confirmed)
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$248.50M$3.7241.9221.72N/A8.23%23.07%8.96%N/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-$123.41M-$4.05N/AN/AN/A-25.05%-56.38%-28.63%5/2/2024 (Estimated)
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.57N/AN/AN/A-21.69%-30.22%-15.17%4/24/2024 (Estimated)

Latest HRC, GMED, NVRO, IRTC, and HAE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Haemonetics Co. stock logo
HAE
Haemonetics
$0.88N/A-$0.88N/AN/AN/A  
5/7/2024N/A
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.55N/A-$0.55N/AN/AN/A  
2/22/2024Q4 2023
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
-$0.60-$1.26-$0.66-$1.26$131.14 million$132.51 million
2/21/2024Q4 2023
Nevro Corp. stock logo
NVRO
Nevro
-$0.50-$0.15+$0.35-$0.05$115.93 million$116.18 million
2/20/2024Q4 2023
Globus Medical, Inc. stock logo
GMED
Globus Medical
$0.59$0.60+$0.01$1.09$608.21 million$616.53 million    
2/8/202412/31/2023
Haemonetics Co. stock logo
HAE
Haemonetics
$0.94$1.04+$0.10$1.47$320.84 million$336.20 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Globus Medical, Inc. stock logo
GMED
Globus Medical
N/AN/AN/AN/AN/A
Haemonetics Co. stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
$0.960.62%N/A25.81%N/A
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Globus Medical, Inc. stock logo
GMED
Globus Medical
0.10
4.88
2.72
Haemonetics Co. stock logo
HAE
Haemonetics
0.91
2.92
1.76
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.97
1.38
1.05
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.17
2.15
2.02
Nevro Corp. stock logo
NVRO
Nevro
0.72
6.37
4.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
95.16%
Haemonetics Co. stock logo
HAE
Haemonetics
99.67%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
76.45%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
N/A
Nevro Corp. stock logo
NVRO
Nevro
95.52%

Insider Ownership

CompanyInsider Ownership
Globus Medical, Inc. stock logo
GMED
Globus Medical
24.30%
Haemonetics Co. stock logo
HAE
Haemonetics
1.79%
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
0.69%
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
0.43%
Nevro Corp. stock logo
NVRO
Nevro
3.00%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Globus Medical, Inc. stock logo
GMED
Globus Medical
5,000135.37 million102.48 millionOptionable
Haemonetics Co. stock logo
HAE
Haemonetics
3,03450.79 million49.88 millionOptionable
Hill-Rom Holdings, Inc. stock logo
HRC
Hill-Rom
10,00066.05 million65.59 millionOptionable
iRhythm Technologies, Inc. stock logo
IRTC
iRhythm Technologies
2,00031.12 million30.99 millionOptionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.68 million35.58 millionOptionable

HRC, GMED, NVRO, IRTC, and HAE Headlines

SourceHeadline
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
finance.yahoo.com - April 17 at 10:38 AM
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
prnewswire.com - April 17 at 8:30 AM
Nevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of CanadaNevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of Canada
americanbankingnews.com - April 16 at 3:44 AM
Nevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of CanadaNevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of Canada
marketbeat.com - April 15 at 3:31 PM
Mizuho Lowers Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Lowers Nevro (NYSE:NVRO) Price Target to $16.00
americanbankingnews.com - April 13 at 5:32 AM
Nevro Corp. (NYSE:NVRO) Receives Consensus Rating of "Hold" from AnalystsNevro Corp. (NYSE:NVRO) Receives Consensus Rating of "Hold" from Analysts
americanbankingnews.com - April 12 at 2:34 AM
Nevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by AnalystsNevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by Analysts
marketbeat.com - April 12 at 2:33 AM
Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00
marketbeat.com - April 11 at 8:25 AM
Nevro (NYSE:NVRO) Trading Up 5.5%Nevro (NYSE:NVRO) Trading Up 5.5%
marketbeat.com - April 9 at 12:12 PM
Nevro (NYSE:NVRO) PT Lowered to $14.00 at Wells Fargo & CompanyNevro (NYSE:NVRO) PT Lowered to $14.00 at Wells Fargo & Company
americanbankingnews.com - April 9 at 4:56 AM
Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)
marketbeat.com - April 5 at 4:35 AM
Where Nevro Stands With AnalystsWhere Nevro Stands With Analysts
benzinga.com - April 3 at 1:52 PM
Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00
marketbeat.com - April 3 at 12:14 PM
Nevro (NYSE:NVRO) Stock Price Down 4.8%Nevro (NYSE:NVRO) Stock Price Down 4.8%
marketbeat.com - April 1 at 2:58 PM
EnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology Commercialization
finanznachrichten.de - March 25 at 4:30 PM
Heres Why You Should Retain Nevro (NVRO) Stock for NowHere's Why You Should Retain Nevro (NVRO) Stock for Now
zacks.com - March 21 at 1:36 PM
Nevro Corp. (NYSE:NVRO) Given Consensus Rating of "Hold" by AnalystsNevro Corp. (NYSE:NVRO) Given Consensus Rating of "Hold" by Analysts
marketbeat.com - March 18 at 2:40 AM
NVRO Mar 2024 20.000 putNVRO Mar 2024 20.000 put
finance.yahoo.com - March 11 at 12:27 AM
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral ScrewNevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
zacks.com - February 29 at 8:31 AM
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
prnewswire.com - February 28 at 4:10 PM
Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)
markets.businessinsider.com - February 27 at 1:07 AM
Nevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market UncertaintyNevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market Uncertainty
markets.businessinsider.com - February 26 at 7:38 AM
Nevro just downgraded at Oppenheimer, heres whyNevro just downgraded at Oppenheimer, here's why
realmoney.thestreet.com - February 23 at 2:42 AM
Nevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
finanznachrichten.de - February 22 at 9:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Globus Medical logo

Globus Medical

NYSE:GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Haemonetics logo

Haemonetics

NYSE:HAE
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot including collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Hill-Rom logo

Hill-Rom

NYSE:HRC
Hill-Rom Holdings, Inc. operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions. The Front Line Care segment offers respiratory care products and sells medical diagnostic equipment and a diversified portfolio of devices. The Surgical Solutions segment supplies surgical products including tables, lights, pendants, positioning devices, various other surgical products and accessories. The company was founded by William A. Hillenbrand on August 7, 1969 and is headquartered in Chicago, IL.
iRhythm Technologies logo

iRhythm Technologies

NASDAQ:IRTC
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.